- Zacks•2 days ago
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.
- American City Business Journals•3 days ago
Cambridge-based Merrimack Pharmaceuticals has been hit with multiple lawsuits in the wake of a major overhaul that includes the sale of its top drug to a French company, according to a federal filing. Merrimack (MACK) announced in January that it was selling its pancreatic cancer drug Onivyde, along with a generic version of ovarian cancer drug Doxil, to Paris-based Ipsen for $575 million. Merrimack also said it was cutting its headcount from more than 400 to 80, while refocusing on a handful of early-stage drugs in its pipeline.
- PR Newswire•3 days ago
CAMBRIDGE, Mass., March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. "The initiation of this study is an important step in evaluating MM-310's safety and preliminary activity in patients diagnosed with solid tumors," said Vasileios Askoxylakis, MD, PhD, Medical Director and MM-310 Project Leader at Merrimack.
MACK : Summary for Merrimack Pharmaceuticals, Inc. - Yahoo Finance
Merrimack Pharmaceuticals, Inc. (MACK)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.90 x 500|
|Ask||3.01 x 5200|
|Day's Range||2.96 - 3.06|
|52 Week Range||2.83 - 9.02|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|